RGNX
Price
$8.39
Change
-$0.36 (-4.11%)
Updated
Jun 27 closing price
Capitalization
422.76M
30 days until earnings call
TBPH
Price
$10.73
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
561.01M
42 days until earnings call
Interact to see
Advertisement

RGNX vs TBPH

Header iconRGNX vs TBPH Comparison
Open Charts RGNX vs TBPHBanner chart's image
REGENXBIO
Price$8.39
Change-$0.36 (-4.11%)
Volume$1.19M
Capitalization422.76M
Theravance Biopharma
Price$10.73
Change-$0.00 (-0.00%)
Volume$50
Capitalization561.01M
RGNX vs TBPH Comparison Chart in %
Loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGNX vs. TBPH commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Buy and TBPH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (RGNX: $8.39 vs. TBPH: $10.73)
Brand notoriety: RGNX and TBPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 103% vs. TBPH: 0%
Market capitalization -- RGNX: $422.76M vs. TBPH: $561.01M
RGNX [@Biotechnology] is valued at $422.76M. TBPH’s [@Biotechnology] market capitalization is $561.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileTBPH’s FA Score has 0 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • TBPH’s FA Score: 0 green, 5 red.
According to our system of comparison, TBPH is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 4 TA indicator(s) are bullish while TBPH’s TA Score has 6 bullish TA indicator(s).

  • RGNX’s TA Score: 4 bullish, 5 bearish.
  • TBPH’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, TBPH is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а -0.47% price change this week, while TBPH (@Biotechnology) price change was +0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

RGNX is expected to report earnings on Jul 30, 2025.

TBPH is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TBPH($561M) has a higher market cap than RGNX($423M). TBPH YTD gains are higher at: 14.028 vs. RGNX (8.538). TBPH has higher annual earnings (EBITDA): -42.3M vs. RGNX (-122.44M). RGNX has more cash in the bank: 268M vs. TBPH (131M). TBPH has less debt than RGNX: TBPH (48.2M) vs RGNX (79.8M). RGNX has higher revenues than TBPH: RGNX (157M) vs TBPH (65.3M).
RGNXTBPHRGNX / TBPH
Capitalization423M561M75%
EBITDA-122.44M-42.3M289%
Gain YTD8.53814.02861%
P/E RatioN/AN/A-
Revenue157M65.3M240%
Total Cash268M131M205%
Total Debt79.8M48.2M166%
FUNDAMENTALS RATINGS
RGNX vs TBPH: Fundamental Ratings
RGNX
TBPH
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
5742
P/E GROWTH RATING
1..100
21100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TBPH's Valuation (41) in the Pharmaceuticals Other industry is in the same range as RGNX (73) in the Biotechnology industry. This means that TBPH’s stock grew similarly to RGNX’s over the last 12 months.

TBPH's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as RGNX (100) in the Biotechnology industry. This means that TBPH’s stock grew similarly to RGNX’s over the last 12 months.

TBPH's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as RGNX (97) in the Biotechnology industry. This means that TBPH’s stock grew similarly to RGNX’s over the last 12 months.

TBPH's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as RGNX (57) in the Biotechnology industry. This means that TBPH’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for TBPH (100) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew significantly faster than TBPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXTBPH
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
60%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
74%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 19 days ago
75%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 19 days ago
74%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
57%
Aroon
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGCIX128.181.10
+0.87%
Gabelli Growth I
LIRVX9.520.08
+0.85%
Lord Abbett International Value R6
ICPUX6.30-0.01
-0.16%
Integrity Mid-North American Resources C
HFMVX35.85-0.11
-0.31%
Hartford MidCap R6
DUKR0.20-0.02
-10.98%
Duke Robotics Corp.

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with DNLI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-4.11%
DNLI - RGNX
58%
Loosely correlated
-2.69%
ARWR - RGNX
55%
Loosely correlated
+0.06%
BEAM - RGNX
53%
Loosely correlated
-1.98%
ARCT - RGNX
52%
Loosely correlated
-7.49%
VYGR - RGNX
51%
Loosely correlated
-0.34%
More

TBPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with KYMR. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
N/A
KYMR - TBPH
40%
Loosely correlated
-3.48%
BPMC - TBPH
38%
Loosely correlated
-0.03%
ELEV - TBPH
38%
Loosely correlated
-5.90%
RGNX - TBPH
33%
Loosely correlated
-4.11%
AUTL - TBPH
32%
Poorly correlated
N/A
More